Fundraising FoxAmgen Ventures — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Max Mumbach(Founding Scientist, Target Discovery)inJeffrey Verboon(Founding Scientist, Computational Biology)inAnsu Satpathy(Founder)Kevin Parker, PhD(Chief Executive Officer, Board Director; co-founder)Ansuman Satpathy, MD, PhD(Co-founder; Board Director)Howard Chang(Founder)in
Co-investors8VCAndreessen HorowitzArtis VenturesCatalio Capital Management, LPFinchley Healthcare VenturesGaingels+9 more
__Twitter.png)
Develops programmable mRNA therapies that last longer and target cells more precisely for cancer and other diseases.
BiotechBoston, US
Tasuku Kitada(Executive Officer, Director, Promoter)inJacob Becraft(Executive Officer, Director, Promoter)inSamta Kundu(Executive Officer)in
BoardJeb Keiper(Director)inAla Alenazi(Director)inPegah Ebrahimi(Director)in
Co-investorsJIC Venture Growth InvestmentsKinnevikPlayground GlobalANRIFPVICONIQ+3 more
Strand is a clinical-stage biotechnology company developing programmable mRNA therapeutics for cancers and autoimmune diseases.
AI & Machine LearningBiotechMedical DevicesBoston, US
Jacob Becraft(CEO, Co-Founder)inTasuku Kitada(President, Head of R&D, Co-founder)inRon Weiss(Scientific Co-founder)inDarrell J. Irvine(Scientific Co-founder)inPrashant Nambiar(Chief Scientific Officer)Ethan Cash(Senior Vice President, Head of Portfolio Management and Program Development)in
Co-investorsAlix VenturesAtinum Investment Co. Ltd.FPVLG Technology VenturesPlayground GlobalPotentum Partners+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.